{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:24:21Z","timestamp":1781328261709,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic Hand Eczema (CHE) is a heterogeneous fluctuating inflammatory disease that represents a significant burden. Effective treatment options for moderate to severe CHE are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess how patients with moderate to severe CHE are treated in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective, physician\u2010led patient record review assessed the demographic, clinical and treatment characteristics of patients aged \u226518\u2009years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital\u2010based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7\u2009months. Overall, 62.9% of patients received systemic therapy and almost one\u2010quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and\/or topical calcineurin inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with moderate to severe CHE, most received systemic therapy with one\u2010quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cod.14477","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T07:54:05Z","timestamp":1704182045000},"page":"365-371","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The management of Chronic Hand Eczema: A retrospective patient record review"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-5262","authenticated-orcid":false,"given":"Emma","family":"Borg","sequence":"first","affiliation":[{"name":"LEO Pharma A\/S  Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Munro","sequence":"additional","affiliation":[{"name":"Lumanity  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Thoning","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S  Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16061"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01164-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2011.01915.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14035"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13804"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13113"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.360"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12973"},{"issue":"5","key":"e_1_2_9_10_1","first-page":"562","article-title":"Quality of life, anxiety, depression, social anxiety and avoidance in patients with chronic hand eczema","volume":"156","author":"Maden S","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12130"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000598"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00669-6"},{"issue":"4","key":"e_1_2_9_14_1","article-title":"Interventions for hand eczema","volume":"4","author":"Christoffers WA","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16081"},{"key":"e_1_2_9_16_1","unstructured":"European Medicines Agency.Updated measures for pregnancy prevention during retinoid use. 21 June 2018 EMA\/261767\/2018. European Medicines Agency. Accessed June 26 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/retinoid-containing-medicinal-products"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S292504"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1632"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10427.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13477"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13015"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2015.06.002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.117856"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.043"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1589641"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08487.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1256"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12362"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07531.x"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.14477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T02:06:43Z","timestamp":1718676403000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cod.14477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/cod.14477"],"URL":"https:\/\/doi.org\/10.1111\/cod.14477","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}